pfizer - Search News

Pfizer names former FDA director

Reuters on MSN · 1d

Pfizer names former FDA director as chief medical officer

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its regulatory and drug safety operations.

Patrizia Cavazzoni, former head of FDA’s drug center, joins Pfizer as chief medical officer

Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, will join Pfizer as chief medical officer.

Bloomberg on MSN · 1d

Pfizer Names Former FDA Drug Chief as Top Doctor

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

Pfizer, Summit and ADCs

FierceBiotech · 1d

Pfizer to test Summit's white-hot bispecific with ADCs

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Miami-based Summit holds the rights to the PD-1xVEGF bispecific ivonescimab in territories including the U.

Seeking Alpha · 1d

Pfizer: What The Summit Therapeutics Deal Brings

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.

BioPharma Dive · 1d

Summit partners with Pfizer to study bispecific, ADC combinations

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially landscape-changing combinations.”

Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma

The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

12h

Pfizer price target lowered to $30 from $32 at Bernstein

Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...

4don MSN

Trump Introducing Pfizer CEO Sparks Loud Booing Inside White House

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

15h

Pfizer (PFE) Gets a Hold from Bernstein

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

7don MSN

3 Things You Need to Know If You Buy Pfizer Today

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

1d

Pfizer shelves Beqvez, a Spark Therapeutics developed product

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

1d

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results